Clinical Trials Logo

Lung Neoplasms clinical trials

View clinical trials related to Lung Neoplasms.

Filter by:

NCT ID: NCT05278754 Not yet recruiting - Central Lung Cancer Clinical Trials

Independent Predictors Analysis and Model Construction of Cavitary Central Lung Cancer

Start date: March 12, 2022
Phase:
Study type: Observational

This study is a retrospective, multicenter clinical study. The main goal is to identify the risk factors for cavity formation in central-type lung cancer lesions, and to construct a prediction model for cavity formation in central-type lung cancer lesions based on the above risk factors.

NCT ID: NCT05278052 Recruiting - Clinical trials for Oligometastatic Disease

Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC

TARGET-02
Start date: April 20, 2020
Phase: Phase 3
Study type: Interventional

Standard Maintenance Therapy versus Local Consolidative Radiation Therapy and standard maintenance therapy in 1-5 sites of OligoMetastatic Non-small cell lung cancer (NSCLC): A Phase III Randomized Controlled Trial

NCT ID: NCT05277844 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC

TARGET-01
Start date: November 11, 2019
Phase: Phase 2
Study type: Interventional

A Phase II randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic Non-small cell lung cancer patients.

NCT ID: NCT05276726 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1

Start date: August 17, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

Evaluate the safety and tolerability, drug levels, and clinical activity of JAB-21822 in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors with KRAS p.G12C mutation and a serine/threonine kinase 11 (STK11) co-mutation.

NCT ID: NCT05275868 Recruiting - Clinical trials for Non-small Cell Lung Cancer

Study of MGY825 in Patients With Advanced Non-small Cell Lung Cancer

Start date: October 5, 2022
Phase: Phase 1
Study type: Interventional

Study of MGY825 single agent in adult patients with advanced non-small cell lung cancer.

NCT ID: NCT05275673 Terminated - Clinical trials for Non-Small Cell Lung Cancer

A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer

Start date: April 15, 2022
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, open-label Phase 2 study of sapanisertib in biomarker-defined populations of sqNSCLC. Patients with NFE2L2 (the name for gene encoding the protein called NRF2)-mutated or wild-type sqNSCLC should have disease that has progressed on or after at least two prior systemic therapies for metastatic disease including platinum-doublet chemotherapy and a programmed cell death 1 ligand 1 (PD-L1) inhibitor. The study will evaluate sapanisertib monotherapy in patients with relapsed/refractory sqNSCLC as two separate groups: Group A: NFE2L2-mutated sqNSCLC and Group B: NFE2L2-WT sqNSCLC.

NCT ID: NCT05274451 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study to Investigate LYL797 in Adults With Solid Tumors

Start date: March 29, 2022
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety and tolerability of LYL797, a ROR1-targeted CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC). The first part of the study will determine the safe dose for the next part of the study, and will enroll TNBC and NSCLC patients. The second part of the study will test that dose in additional TNBC and NSCLC patients.

NCT ID: NCT05273814 Not yet recruiting - Clinical trials for Non-Small Cell Lung Cancer

Study of Chemotherapy and PD-1 Inhibitor Combination With Anti-angiogenesis to Treat Elderly Lung Cancer

Start date: August 1, 2022
Phase: Phase 1
Study type: Interventional

This single-center, open-label, phaseâ… study is to evaluate the efficacy of Tislelizumab in combination with Bevacizumab and Pemetrexed for the first-line treatment of advanced Non-squamous Non-small Cell lung cancer in Elderly Patients

NCT ID: NCT05271916 Recruiting - Clinical trials for Non-Small Cell Lung Cancer (NSCLC)

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Start date: October 13, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open label, Phase I/IIB study investigating the efficacy and safety of treatment with dacomitinib plus anlotinib as first-line therapy for patients with advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) 21-L858R mutations. This study comprises two parts: 1. A dose escalation Phase I study to determine the recommended phase II dose. 2. a multi-center, open label, randomized controlled, Phase IIB study.

NCT ID: NCT05270395 Recruiting - Lung Cancer Clinical Trials

Piloting 'mPal,' a Multilevel Strategy for Palliative Care Implementation

Start date: July 28, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to assess the feasibility and acceptability of mPal, a multilevel implementation strategy to improve palliative care use among advanced stage lung cancer patients receiving cancer treatment.